Safety and Morbidity of First and Repeat Transrectal Ultrasound Guided Prostate Needle Biopsies: Results of a Prospective European Prostate Cancer Detection Study

Djavan, Bob; Waldert, Matthias; Zlotta, Alexandre R.; Dobroński, P.; Seitz, Christian; Remzi, Mesut; Borkowski, Andrzej; Schulman, Claude; Marberger, Michael

doi:10.1016/s0022-5347(05)65851-x

Cited by 1,430 publications

(200 citation statements)

References 32 publications

Supporting

Mentioning

157

Contrasting

Unclassified

Order By: Relevance

“…2 It is generally well tolerated, with no sedation, by most men. The reported major complication rate is less than 1%.…”

Section: Discussionmentioning

confidence: 99%

“…The reported major complication rate is less than 1%. 2,15 In contrast, minor complications are frequent, with 60-79%. 5,16 Most of these complications do not require any intervention and are selflimiting.…”

Section: Discussionmentioning

confidence: 99%

“…1 Transrectal ultrasound (TRUS)-guided prostate needle biopsy (PB) is a simple and reliable technique to obtain prostatic tissue for histological evaluation. [2][3][4] Most men with elevated PSA or abnormal digital rectal examination (DRE) undergo TRUS-PB. In the face of low morbidity, the TRUS-PB is performed as an outpatient procedure.…”

Section: Introductionmentioning

confidence: 99%

“…In the face of low morbidity, the TRUS-PB is performed as an outpatient procedure. 2,[5][6][7] Although the incidence of major complications associated with TRUS-BP is low, minor complications such as urinary tract infection, dysuria, hematuria and hemospermia are frequent. 2,6 Although many studies have reported the incidence of complications, they were not specifically designed to evaluate the true complication rate and its implications.…”

Section: Introductionmentioning

confidence: 99%

“…2,[5][6][7] Although the incidence of major complications associated with TRUS-BP is low, minor complications such as urinary tract infection, dysuria, hematuria and hemospermia are frequent. 2,6 Although many studies have reported the incidence of complications, they were not specifically designed to evaluate the true complication rate and its implications. [8][9][10][11][12] It is essential to have a clear understanding of the true morbidity of this procedure, and this would enable appropriate patient counseling.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Hemospermia following transrectal ultrasound-guided prostate biopsy: a prospective study

Manoharan

Ayyathurai

Nieder

et al. 2007

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Hemospermia is known to be associated with transrectal ultrasound-guided prostate biopsy (TRUS-PB). The true incidence of hemospermia, its duration and implications are not well established. We performed a prospective observational study involving patients undergoing TRUS-PB for suspected prostate cancer at our institution. Sixty-three eligible men were included in the study. Most men (84%) undergoing TRUS-PB, who were able to ejaculate, experienced hemospermia, which was associated with some degree of anxiety. The mean duration of hemospermia was 3.5 (71.7) weeks. The number of ejaculations before the complete resolution of hemospermia was 8 (76.7). None of the clinical and pathological factors was a significant predictor of the duration of hemospermia. Patients should be adequately counseled before TRUS-PB to avoid undue anxiety and alterations in sexual activity.

show abstract

“…2 It is generally well tolerated, with no sedation, by most men. The reported major complication rate is less than 1%.…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Hemospermia following transrectal ultrasound-guided prostate biopsy: a prospective study

Manoharan

Ayyathurai

Nieder

et al. 2007

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

show abstract

Risk of the “Androgen Deprivation Syndrome” in Men Receiving Androgen Deprivation for Prostate Cancer

Shahinian

Kuo

Freeman³

et al. 2006

Arch Intern Med

View full text Add to dashboard Cite

Background: Androgen deprivation therapy for prostate cancer has been associated with a spectrum of adverse effects, such as depression, memory difficulties, and fatigue, termed the androgen deprivation syndrome. Primary care physicians providing follow-up care for men with prostate cancer will be faced with managing these effects. We therefore sought to estimate the incidence of these effects and, by using a control group, ascertain whether these effects were related to androgen deprivation itself. Methods: We assessed the risk of physician diagnoses of depression, cognitive impairment, or constitutional symptoms in Medicare data following androgen deprivation using a sample of 50 613 men with incident prostate cancer and 50 476 men without cancer, from 1992 through 1997, in the linked Surveillance, Epidemiology, and End Results-Medicare database. Cox proportional hazards regression was used to adjust for confounding variables. Results: Of men surviving at least 5 years after diagnosis, 31.3% of those receiving androgen deprivation developed at least 1 depressive, cognitive, or constitutional diagnosis compared with 23.7% in those who did not (PϽ.001). After adjustment for variables such as comorbidity, tumor characteristics, and age, the risks associated with androgen deprivation were substantially reduced or abolished: relative risk (RR) for depression diagnosis, 1.08 (95% confidence interval [CI], 1.02-1.15); RR for cognitive impairment, 0.99 (95% CI, 0.94-1.04); and RR for constitutional symptoms, 1.17 (95% CI, 1.13-1.22). Conclusion: Depressive, cognitive, and constitutional disorders occur more commonly in patients receiving androgen deprivation, but this appears to be primarily because patients receiving androgen deprivation are older and have more comorbid conditions and more advanced cancers.

show abstract

Active Surveillance Compared With Initial Treatment for Men With Low-Risk Prostate Cancer

Hayes¹,

Ollendorf²,

Pearson³

et al. 2010

JAMA

243

156

View full text Add to dashboard Cite

Safety and Morbidity of First and Repeat Transrectal Ultrasound Guided Prostate Needle Biopsies: Results of a Prospective European Prostate Cancer Detection Study

Cited by 1,430 publications

References 32 publications

Hemospermia following transrectal ultrasound-guided prostate biopsy: a prospective study

Hemospermia following transrectal ultrasound-guided prostate biopsy: a prospective study

Risk of the “Androgen Deprivation Syndrome” in Men Receiving Androgen Deprivation for Prostate Cancer

Active Surveillance Compared With Initial Treatment for Men With Low-Risk Prostate Cancer

Contact Info

Product

Resources

About